![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Termination of development of the novel compound AVP-786 (deudextromethorphan HBr), in development for the treatment of agitation associated with dementia due to Alzheimer's.
Lead Product(s): Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area: Neurology Product Name: AVP-786
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2024
Details:
AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) is a combinational a CYP2D6 inhibitor. It is being evaluated for the treatment of dementia due to Alzheimer’s disease.
Lead Product(s): Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area: Neurology Product Name: AVP-786
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Avanir and Otsuka have always shared a deep commitment to advancing solutions that improve the lives of patients by Nuedexta (dextromethorphan hydrobromide and quinidine sulfate).
Lead Product(s): Deudextromethorphan Hydrobromide,Quinidine sulphate
Therapeutic Area: Neurology Product Name: AVP-786
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Otsuka America Pharmaceutical, Inc.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 24, 2022